#106
|
||||
|
||||
Íàâåðíîå, äåëî â äåôèíèöèÿõ.
 íåêîòîðûõ ñòàòüÿõ åòî âûãëÿäèò ïðèìåðíî òàê: Approximately 90% of patients who have viral upper respiratory tract infections (URTIs) have sinus involvement, but only 5-10% of these patients have bacterial superinfection requiring antimicrobial treatment. Òî åñòü ðå÷ü áóäåò èäòè î ñèíóñèòå òîëüêî â ñëó÷àå áàêòåðèàëüíîé èíôåêöèè. Òî åñòü â òåõ ñëó÷àÿõ, êîãäà íóæíî ëå÷èòü. À ïðè ÎÐÂÈ åòî - sinus involvement.  äðóãèõ, â ÷àñòíîñòè â guidelines ïèøyò î Viral Acute Sinusitis and Bacterial Acute Sinusitis. Òî åñòü ÅNÒ ïî èäåå ñ âèðóñíûìè ñèíóñèòàìè íå äîëæíà èìåòü äåëî. |
#107
|
||||
|
||||
Öèòàòà:
Äî ýòîãî ïðîñòî ðèíîñèíóñèò. Èìåòü ââèäó, âèðóñíûé, áàêòåðèàëüíûé, êîíå÷íî áóäåì, îïèðàÿñü íà ýïèä. äàííûå, îäíàêî òîëüêî äëÿ ñåáÿ. |
#108
|
||||
|
||||
Viral rhinosinusitis (VRS)
A clinician should diagnose VRS when: a. symptoms or signs of acute rhinosinusitis are present less than 10 days and the symptoms are not worsening. Acute bacterial rhinosinusitis (ABRS) A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis are present 10 days or more beyond the onset of upper respiratory symptoms, or b. symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#109
|
||||
|
||||
Âèðóñíûé îò áàêòåðèàëüíîãî îòëè÷àþò êàê ïðàâèëî êëèíè÷åñêè., è ëå÷åíèå ïðèíöèïèàëüíî ðàçíîå. Ïî÷èòàéòå ïîñò îò Yananshs. À ËÎÐèêè äåéñòâèòåëüíî ÷àùå èìåþò äåëî ñ áàêòåðèàëüíûì ñèíóñèòîì, ïîñêîëüêó áîëüíîé ïîïàäàåò ê ËÎÐ-âðà÷ó ïîñëå òåðàïåâòà, êîãäà óñïåâàåò ïðèñîåäèíèòüñÿ áàêòåðèàëüíàÿ èíôåêöèÿ.
|
#110
|
||||
|
||||
|
#111
|
||||
|
||||
Ìîè ñëîâà:
Öèòàòà:
[quote] Öèòàòà:
ìîäåðèðîâàíî Ñîððè, ó ìåíÿ âïå÷àòëåíèå, ÷òî ìû íà ðàçíûõ ÿçûêàõ âåäåì áåñåäó. |
#112
|
||||
|
||||
To Yananshs, êîíå÷íî, òåðàïåâòû òàê æå ìîãóò íàçíà÷àòü àíòèáèîòèêè è ïðè íåýôôåêòèâíîñòè, ïàöèåíòà îòïðàâëÿþò ê ËÎÐó.
To Morphey, Âû âñå åùå íàçíà÷àåòå àçèòðîìèöèí íà 14 äíåé? http://forums.rusmedserv.com/showpos...39&postcount=8 È äî ñèõ ïîð äóìàåòå, ÷òî ôðîíòèò è ñèíóñèò - ýòî ðàçíûå ïîíÿòèÿ? (Âî ïåðâûõ, îòêóäà Âû âçÿëè, ÷òî ó áîëüíîé èìåííî ôðîíòèò? Ýòî åùå íåèçâåñòíî. Ïîêà ìû èìååì äåëî ñ ñèíóñèòîì, íå áîëåå.) http://forums.rusmedserv.com/showpos...74&postcount=9 Äà è âîîáùå, ñïîñîáû âåñòè ñïîðû, â áîëüøèíñòâå ñëó÷àåâ ýìîöèè íå áîëåå, íå äîñòîéíû âðà÷à. (íå ãîâîðÿ óæå î EBM) ìîäåðèðîâàíî |
#113
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Âîò ýòî, êàê ãîâîðèòñÿ, îòæèã À â îáùåì-òî î ÷åì ðàçãîâîð? ×òî ÷àùå - âîâëå÷åíèå ñëèçèñòîé ñèíóñîâ â ðèíîâèðóñíóþ èíôåêöèþ èëè áàêòåðèàëüíûé ñèíóñèò? Äà âðîäå áû "âîâëå÷åíèå". À âîâëå÷åíèå - ýòî âîñïàëåíèå? Äà âðîäå áû âîñïàëåíèå À âîñïàëåíèå - ýòî ñèíóñèò. À ñïîðîâ-òî! |
#114
|
|||
|
|||
À êàêîâ â îáùåì òî ðàçãîâîð? ×òî ÷àùå - ïðèâåäåíèå àðãóìåòîâ èëè ïåðåõîä íà îöåíêó îïïîíåíòà? Äà âðîäå áû ïîêà "àðãóìåíòû" À ïåðåõîäû ïîÿâèëèñü? À ïåðåõîäû ïîÿâèëèñü. È ïðè èõ ïðîäîëæåíèè âîñïîñëåäóþò ñàíêöèè äëÿ ëþáîãî ó÷àñòíèêà. È ñïîðîâ-òî.....
__________________
Ñ óâàæåíèåì, Âàëåðèé Âàëåðüåâè÷ Ñàìîéëåíêî |
#115
|
|||
|
|||
Òåìà íàçûâàåòñÿ Òàêòèêà ïðè ñèíóñèòå.
Íó è êàêîâà òàêòèêà ïðè Ac.viral sinusitis? È ÷åì îíà îòëè÷àåòñÿ îò òàêòèêè ïðè Common cold (Viral URTI)? Íàñêîëüêî ÿ ïîíèìàþ, íè÷åì. Âìåøàòåëüñòâî ( óïîòðåáëþ ýòî ñëîâî ) íåîáõîäèìî òîëüêî ïðè áàêòåðèàëüíîì ñèíóñèòå. Íåò? Òîãäà, î ÷åì ìû ñïîðèì? Î òåðìèíàõ? Ìåíÿ, êàê ïåäèàòðà, èíòåðåñóåò Öèòàòà:
|
#116
|
||||
|
||||
Dr. Ira, íàñêîëüêî ÿ ïîìíþ Âû ñàìè ðåøèëè ïîñïîðèòü îá ýòèîëîãèè ñèíóñèòîâ? ïî-ìîåìó ìû ïðèøëè ê êîíñåíñóñó...
À òàêòèêà ïðè ñèíóñèòå â ïåðâóþ î÷åðåäü çàêëþ÷àåòñÿ â ðåøåíèè âîïðîñà î íàçíà÷åíèè àíòèáèîòèêîâ, ïîñêîëüêó ýòî íå âñåãäà òðåáóåòñÿ (ïðè âèðóñíîé ýòèîëîãèè) ×òî êàñàåòñÿ òåðàïèè ïðè áàêòåðèàëüíîì ñèíóñèòå, òî ýòî óæå îáñóæäàëîñü, ÿ îáîáùèëà òàêòèêó ëå÷åíèÿ ñèíóñèòîâ â ýòîì ñîîáùåíèè: http://forums.rusmedserv.com/showpos...62&postcount=3 |
#117
|
||||
|
||||
Íà âñÿêèé ñëó÷àé (ìíå ñàìîìó èíòåðåñíî ëå÷åíèå ñèíóñèòîâ, ïîñêîëüêó íåñêîëüêî ðàç â íåäåëþ ÿ ïðèòâîðÿþñü ñåìåéíûì âðà÷îì ÷òîáû îòäîõíóòü îò òÿæåëîãî è äåìåíòíîãî êîíòèíãåíòà) ñóììèðóþ (ñóììèðóþ íå ÿ, ÿ ïóáëèêóþ ):
SUMMARY AND RECOMMENDATIONS Acute rhinosinusitis (ARS), inflammation of the nasal cavity and paranasal sinuses lasting less than four weeks, is subdivided into acute viral rhinosinusitis (AVRS) and acute bacterial rhinosinsitis (ABRS). ABRS occurs in 0.5 to 2 percent of episodes. (See "Introduction" above and see "Pathophysiology" above). The diagnosis of ARS is based on the presence of 1) purulent rhinorrhea and 2) nasal congestion and/or facial pain. Symptoms do not accurately distinguish viral from bacterial infection. ABRS is suggested by the presence of symptoms for seven or more days, especially if symptoms initially improve and then worsen. Cultures from nasal swabs or secretions are inaccurate. Radiography is generally not indicated in the initial evaluation of ARS. (See "Diagnosis" above). AVRS is expected to resolve within ten days; ABRS may also resolve spontaneously within the first ten days. Patients who present with fewer than 10 days of symptoms, in the absence of high fever or symptoms suggesting complicated illness, should be managed with supportive care. We suggest mild analgesics, systemic or limited-duration topical decongestants, and fluid (Grade 2C). We suggest treatment with intranasal glucocorticoids (Grade 2B). We suggest not treating symptoms with antihistamines or zinc (Grade 2B). (See "Indications for urgent referral" above and see "Acute viral rhinosinusitis" above). We suggest that patients with mild symptoms lasting more than ten days be treated with observation and supportive therapy (as above) for an additional seven days (Grade 2C). (See "Observation" above). We suggest treatment with an antibiotic for patients with moderate to severe symptoms of ABRS (T >101, severe pain), or for patients whose symptoms worsen during observation (Grade 2B). We recommend a narrow spectrum antibiotic for empiric therapy (Grade 1A). Our preference is for amoxicillin 500 mg three times a day for 10 to 14 days; trimethoprim-sulfamethoxazole and macrolides are alternatives. We suggest topical glucocorticoids as adjunctive therapy (Grade 2B). (See "Antimicrobials" above and see "Topical glucocorticoids" above). Nosocomial ABRS is relatively common in patients with prolonged nasotracheal intubation, and often involves gram negative organisms. Nasal foreign bodies should be removed and patients treated with culture-directed antibiotic therapy. Immunosuppressed patients are at risk for acute fulminant invasive fungal rhinosinusitis; treatment involves endoscopic biopsy, emergency surgical debridement, and systemic antifungal therapy. (See "Nosocomial bacterial rhinosinusitis" above and see "Acute invasive fungal rhinosinusitis" above). Complications of ABRS occur rarely, and include orbital cellulitis, osteitis, and meningitis. (See "Complications" above). Use of UpToDate is subject to the Subscription and License Agreement. ß áû ïîïðîñèë îïóáëèêîâàòü êëèíè÷åñêèé ñëó÷àé ïàöèåíòà, òðåáóþùåãî ïóíêöèè. Ñ èñòîðèåé áîëåçíè è ñíèìêîì - îáñóäèì ïðåäìåòíî. Ñåé÷àñ äèñêóññèÿ ïðåâðàùàåòñÿ â ñâàëêó |
#118
|
||||
|
||||
Âîò åùå ïîëåçíàÿ ññûëêà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ðåàëüíûé êëèíè÷åñêèé ñëó÷àé ïîïðîáóþ ïîäîáðàòü. Òàêòèêà ëå÷åíèÿ ñèíóñèòîâ â Ðîññèè è ÑØÀ íå îòëè÷àåòñÿ, êðîìå ÷àñòîòû ïðèìåíåíèÿ ïóíêöèé â/÷ ïàçóõ. |
#119
|
||||
|
||||
2 ÅNÒ 1. Âû ïðèâîäèòå ññûëêè äàæå 28-ëåòíåé äàâíîñòè è øèðîêî öèòèðóåòå e-medicine è medscape - èñòî÷íèêè îáøåé èíôîðìàöèè äëÿ ìëàäøèõ âðà÷åé â ñïåöèàëüíîñòÿõ, óäàë¸ííûõ îò ËÎÐ.
Áîëåå òîãî, åòè ñàéòû íå ÿâëÿþòñÿ ÅBÌ-âåñîìûìè â îòëè÷èe îò óæå ïðåäñòàâëåííûõ íàöèîíàëüíûõ ãàéäîâ, âûïóøåííûõ íå ðàíüøå 2007 è îñíîâàííûõ íà äîêàçàòåëüíîì óðîâíå. |
#120
|
||||
|
||||
Äëÿ íà÷àëà îçíàêîìüòåñü ñ :
Clin Exp Allergy. 2008 Feb;38(2):260-75. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, Dixon TA, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology. The Royal National Throat Nose & Ear Hospital, Gray's Inn Road, London, UK. This guidance for the management of patients with rhinosinusitis and nasal polyposis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The recommendations are based on evidence and expert opinion and are evidence graded. These guidelines are for the benefit of both adult physicians and paediatricians treating allergic conditions. Rhinosinusitis implies inflammation of the nose and sinuses which may or may not have an infective component and includes nasal polyposis. Acute rhinosinusitis lasts up to 12 weeks and resolves completely. Chronic rhinosinusitis persists over 12 weeks and may involve acute exacerbations. Rhinosinusitis is common, affecting around 15% of the population and causes significant reduction in quality of life. The diagnosis is based largely on symptoms with confirmation by nasendoscopy. Computerized tomography scans and magnetic resonance imaging are abnormal in approximately one third of the population so are not recommended for routine diagnosis but should be reserved for those with acute complications, diagnostic uncertainty or failed medical therapy. Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis. There are few good quality trials in this area but the available evidence suggests that treatment is primarily medical, involving douching, corticosteroids, antibiotics, anti-leukotrienes, and anti-histamines. Endoscopic sinus surgery should be considered for complications, anatomical variations causing local obstruction, allergic fungal disease or patients who remain very symptomatic despite medical treatment. Further well conducted trials in clearly defined patient groups are needed to improve management. |